PT  - JOURNAL ARTICLE
AU  - Tani, Naoki
AU  - Ikematsu, Hideyuki
AU  - Goto, Takeyuki
AU  - Gondo, Kei
AU  - Inoue, Takeru
AU  - Yanagihara, Yuki
AU  - Kurata, Yasuo
AU  - Oishi, Ryo
AU  - Minami, Junya
AU  - Onozawa, Kyoko
AU  - Nagano, Sukehisa
AU  - Kuwano, Hiroyuki
AU  - Akashi, Koichi
AU  - Shimono, Nobuyuki
AU  - Chong, Yong
TI  - Correlation of post-vaccination fever with specific antibody response to SARS-CoV-2 BNT162b2 booster and no significant influence of antipyretic medication
AID  - 10.1101/2022.07.25.22277569
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.25.22277569
4099  - http://medrxiv.org/content/early/2022/07/28/2022.07.25.22277569.short
4100  - http://medrxiv.org/content/early/2022/07/28/2022.07.25.22277569.full
AB  - Background A SARS-CoV-2 mRNA vaccine booster elicits sufficient antibody responses that protect against COVID-19, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibody responses have not been fully characterized, nor has the influence of antipyretic use.Methods This is a prospective observational cohort study in Japan, following our prior investigation of BNT162b2 two-dose primary series. Spike-specific IgG titers were measured for SARS-CoV-2-naive hospital healthcare workers who received a BNT162b2 booster. The severity of solicited adverse reactions, including the highest body temperature, and self-medicated antipyretics were reported daily for seven days following vaccination through a web-based self-reporting diary.Results The data of 281 healthcare workers were available. Multivariate analysis extracted fever after the booster dose (beta=0.305, p<0.001) as being significantly correlated with the specific IgG titers. The analysis of 164 participants with data from the primary series showed that fever after the second dose was associated with the emergence of fever after the booster dose (relative risk: 3.97 [95% confidence interval: 2.48-6.35]); however, the IgG titers after the booster dose were not affected by fever after the second dose. There were no significant differences in the IgG titers by the use, type, or dosage of antipyretic medication.Conclusions These results suggest an independent correlation between mRNA vaccine-induced specific IgG levels and post-booster vaccination fever, without any significant influence of fever after the primary series. Antipyretic medications for adverse reactions would not interfere with the elevation of specific IgG titers.summary Spike-specific IgG titers after a BNT162b2 booster were measured for healthcare workers. Adverse reactions and self-medicated antipyretics were reported. Post-booster vaccination fever was correlated with the specific IgG titers. Antipyretics used for adverse reactions did not suppress specific IgG induction.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics review board of Fukuoka City Hospital (approval number 228) and registered in the University Hospital Medical Information Network-Clinical Trials Registry (registration no. UMIN000046246).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors